LVTX•benzinga•
LAVA Therapeutics Announces First Patient Dosed In Phase 1 Study Of Bispecific Anti-CD123 Gammabody LAVA-1266 For AML And MDS; Initial Data Expected By Year-End 2025
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on January 10, 2025 by benzinga